High-purity mesenchymal stem cells

By selecting mesenchymal stem cell clones positive for LNGFR and Thy-1 with specific size and uniformity criteria, the method ensures high-purity, uniform, and high-performance MSCs for clinical use.

KR103045257B1Active Publication Date: 2026-11-06PUREC CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020227015011
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-01-16
Filing Date
2020-04-06
Publication Date
2026-11-06
Estimated Expiration
2040-04-06

AI Technical Summary

Technical Problem

Existing methods for isolating mesenchymal stem cells (MSCs) fail to achieve high purity and uniformity, leading to variations in differentiation and proliferation abilities, and there is a need for improved quality control to ensure consistent cell performance.

Method used

Select mesenchymal stem cell clones that are positive for both LNGFR (CD271) and Thy-1 (CD90), with a coefficient of variation (CV) of forward scattered light in flow cytometry of 35% or less and an average cell size of 20 µm or less, to ensure uniformity and high proliferation and differentiation capabilities.

Benefits of technology

The selected cell population exhibits consistent size, excellent proliferative, and differentiation capabilities, making it suitable for clinical applications in treating various diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure R1020227015011_ABST
    Figure R1020227015011_ABST
Patent Text Reader

Abstract

A cell population of fast-proliferating mesenchymal stem cell clones in which LNGFR (CD271) is positive, or LNGFR (CD271) and Thy-1 (CD90) are contributory positive, satisfying at least one of the following characteristics (a) and (b). (a) The coefficient of variation of forward scattered light in flow cytometry is 35% or less. (b) The average cell size is 20 µm or less.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a high-purity cell population of human mesenchymal stem cells that has uniformity and rapid proliferation. Background Technology

[0002] Mesenchymal stem cells (MSCs) are one of the somatic stem cells that are actively being applied in clinical practice, following hematopoietic stem cells, due to the fact that they have fewer ethical issues associated with cell collection and possess the ability to differentiate into various types such as bone, cartilage, and fat. MSCs are widely used as biomaterials, such as by inducing differentiation into cartilage or bone mainly in vitro and then transplanting them locally, as they can be isolated with relatively simple manual dexterity.

[0003] Furthermore, when proceeding with clinical applications, the ability to manufacture the required amount of cells that maintain a specific function becomes an essential condition for commercialization.

[0004] However, if there is a variation in the properties of the starting material (human bone marrow fluid, etc.), that is, if there is a difference in properties derived from the donor, the properties of the cell preparation as a product are significantly affected.

[0005] For this reason, it is important to obtain high-purity mesenchymal stem cells with minimal variation.

[0006] The inventors have established a purification and isolation method that can eliminate differences in the proliferative capacity of MSCs derived from a donor by isolating LNGFR and Thy-1 donor-positive cells from bone marrow fluid by flow cytometry to obtain a Rapidly Expanding Clone (REC) (Japanese Patent No. 6463029, WO 2016 / 017795, Mabuchi Y. et al., Stem Cell Reports 1 (2): 152-165, 2013). In this method, REC is isolated and selected, for example, using the expression of Ror2 as an indicator.

[0007] In addition, a purified mesenchymal stem cell composition and a method for purifying the mesenchymal stem cell composition are also known (Japanese Patent No. 6025329), and in this method, mesenchymal stem cells with a diameter of 150 μm or less are purified.

[0008] However, variations in differentiation ability and proliferation ability are still observed in REC clones. Furthermore, even with RECs that have excellent proliferation ability, degradation due to passage is unavoidable, so effective quality control methods were required. Also, even when Ror2 expression was used as an indicator, there was room for improvement in the correlation with proliferation ability. Prior art literature

[0009] Japanese Patent No. 6463029 International Publication No. 2016 / 017795 Pamphlet Japanese Patent No. 6025329

[0010] Mabuchi Y Morikawa S, Harada S; Niibe K, Suzuki S, Renault-Mihara F, Houlihan DD, Akazawa C, Okano H, Matsuzaki Y. LNGFR+ Thy-1+ Vcam-1hi+ cells reveal functionally distinct subpopulations in mesenchymal stem cells. Stem Cell Reports 1 (2): 152-165, 2013. The problem to be solved

[0011] Therefore, in the present invention, it was required to establish a selection method for REC with high purity and high uniformity, and an indicator that guarantees cell performance. means of solving the problem

[0012] As a result of conducting a review to solve the above problem, the inventors obtained cells positive for both LNGFR and Thy-1 from human bone marrow fluid, produced numerous REC clones from a single cell, and while repeating the measurement of differentiation ability and proliferation ability, found that the size and uniformity of the cells correlated more strongly with the differentiation ability and proliferation ability of each clone.

[0013] In addition, the inventors analyzed the size and deviation of cells constituting each clone using forward scattered light (FSC) in flow cytometry as an indicator, and found that the smaller the size and the smaller the CV value of FSC, the better the proliferation and differentiation ability. They also found that by selecting each clone based on this indicator, it is possible to produce cells with functions within a certain range.

[0014] That is, the present invention is as follows.

[0015] (1) A cell population of fast-proliferating mesenchymal stem cell clones in which LNGFR (CD271) is positive, or LNGFR (CD271) and Thy-1 (CD90) are consortient-positive, satisfying at least one of the following characteristics (a) and (b).

[0016] (a) The coefficient of variation of forward scattered light in flow cytometry is 35% or less.

[0017] (b) The average cell size is 20 µm or less.

[0018] (2) A cell population described in (1) with a coefficient of variation of 30% or less.

[0019] (3) A cell population described in (1) or (2) having an average cell size of 14 μm to 18 μm.

[0020] (4) A method for evaluating the quality of a cell population of fast-proliferating mesenchymal stem cell clones in which LNGFR (CD271) is positive, or LNGFR (CD271) and Thy-1 (CD90) are conjugated positive, wherein the cell population satisfies at least one of the following (a) and (b) is judged to be of high quality.

[0021] (a) The coefficient of variation of forward scattered light in flow cytometry is 35% or less.

[0022] (b) The average cell size is 20 µm or less.

[0023] (5) A method described in (4) with a coefficient of variation of 30% or less.

[0024] (6) A method described in (4) or (5) having an average cell size of 14 μm to 18 μm.

[0025] (7) A method for selecting a clinically applicable cell population from a cell population of fast-proliferating mesenchymal stem cell clones that are positive for LNGFR (CD271) or positive for both LNGFR (CD271) and Thy-1 (CD90), wherein the cell population satisfies at least one of the following (a) and (b) is selected as a therapeutic mesenchymal stem cell population.

[0026] (a) The coefficient of variation of forward scattered light in flow cytometry is 35% or less.

[0027] (b) The average cell size is 20 µm or less.

[0028] (8) A method described in (7) with a coefficient of variation of 30% or less.

[0029] (9) A method described in (7) or (8) having an average cell size of 14 μm to 18 μm. (10) A culture of a cell population of human mesenchymal stem cells, wherein the cell population is obtained by the steps of: (a) obtaining a population of mesenchymal stem cells that are positive for LNGFR (CD271) or co-positive for LNGFR (CD271) and Thy-1 (CD90); (b) single-cell culturing a clone of the mesenchymal stem cells; and (c) recovering a clone of the rapidly proliferating mesenchymal stem cells, wherein the coefficient of variation of forward scattered light in flow cytometry of the culture is 35% or less. (11) (a) having an average cell size of 20 μm or less, (b) having a coefficient of variation of forward scattered light in flow cytometry of 30% or less, or (c) having an average cell size of 20 μm or less and a coefficient of variation of forward scattered light in flow cytometry of A culture described in (10) having 30% or less. (12) A culture described in (10) or (11) having an average cell size of 14 μm to 18 μm. Effects of the invention

[0030] Through the present invention, it was possible to select a population of mesenchymal stem cells that possess uniformity in cell size and, furthermore, excellent proliferative and differentiation capabilities. The selected cell population has clinically applicable quality and is expected to be used in the treatment of myocardial infarction, cerebral infarction, spinal cord injury, bone or chondrogenesis-related diseases, graft-versus-host disease (GVHD), liver cirrhosis, epidermal bullosis, lower limb ischemia, etc. Brief explanation of the drawing

[0031] FIG. 1 is a diagram showing an overview of a method for selecting REC in the present invention. Figure 2 is a diagram showing the measurement results of the CV values ​​of forward scattered light (FSC) by flow cytometry. Figure 3 is a diagram showing the results of evaluating cell proliferation ability and fat differentiation ability. Figure 4 is a diagram showing the comprehensive analysis results of the REC clone. Figure 5 is a diagram showing the summary of the interpretation results of the present invention. Figure 6 is a diagram showing the comprehensive analysis results of the REC clone. Specific details for implementing the invention

[0032] The present invention will be described in detail below.

[0033] 1. Overview

[0034] The inventors succeeded in isolating a rapidly expanding cell clone (Rapidly Expanding Clone: ​​REC) from LNGFR (CD271)-positive mesenchymal stem cells (CD271+ cells) or LNGFR (CD271) and Thy-1 (CD90)-positive mesenchymal stem cells (CD271+CD90+ cells) through previous research.

[0035] This REC is a cell that can reach confluence in two weeks when seeded and cultured one at a time in a 96-well plate, and compared to mesenchymal stem cells obtained by conventional methods, it possesses more than 1,000 times the ability in proliferation, differentiation, and migration. In particular, because it maintains migration ability, it can be administered intravenously, and thus applications for severe systemic diseases such as osteochondrosis and cartilage dysplasia can be expected.

[0036] However, even among such REC clones, variations in differentiation or proliferation ability are sometimes observed.

[0037] The present invention provides a cell clone with low deviation and a method for selecting said cell clone.

[0038] A cell population comprising the cell clones of the present invention is a population of rapidly proliferating mesenchymal stem cell clones that are contributory to LNGFR (CD271) and Thy-1 (CD90), and satisfies at least one of the following features (a) and (b).

[0039] (a) The coefficient of variation of forward scattered light in flow cytometry is 35% or less.

[0040] (b) The average cell size is 20 µm or less.

[0041] 2. Method for Concentrating Human Mesenchymal Stem Cells

[0042] In the present invention, to obtain mesenchymal stem cells in which LNGFR (CD271) is positive, or in which LNGFR (CD271) and Thy-1 (CD90) are conjugated, the method described in WO 2009 / 31678 may be followed, for example.

[0043] The outline of the method is as follows.

[0044] First, mesenchymal stem cells are highly concentrated by selecting a cell fraction in which LNGFR (CD271) is positive (CD271+) or CD271 and CD90 are co-positive (CD271+CD90+) from a cell population containing human mesenchymal stem cells. Additionally, if hematopoietic cells are included in the cell population containing human mesenchymal stem cells, a process of selecting cells in which CD45 and CD235a are co-negative (CD45-CD235a-) may be added to select non-hematomatous cells.

[0045] Cell populations containing mesenchymal stem cells can be prepared by flow cytometry or affinity chromatography.

[0046] The materials for obtaining this cell population are not particularly limited, but examples include bone marrow or peripheral blood (including peripheral blood after G-CSF administration). Additionally, bone marrow from the spine, sternum, long bones, etc., may be used.

[0047] When preparing cells, if the material consists of a cell mass containing mesenchymal stem cells, physical treatment such as pipetting or enzymatic treatment with trypsin, collagenase, etc. may be performed on the material as needed. In addition, if red blood cells are mixed into the material, it is desirable to lyse the red blood cells in advance.

[0048] Using the cell population prepared as described above, CD271+ cells or CD271+CD90+ cells are selected.

[0049] Methods for selecting CD271+ cells or CD271+CD90+ cells include, for example, the use of antibodies.

[0050] The antibody is an anti-CD271 antibody and / or an anti-CD90 antibody capable of selecting CD271+ cells or CD271+CD90+ cells. When flow cytometry is used for selection, live cells can be selected in a short time by using an anti-CD271 antibody labeled with different fluorescent dyes such as FITC, PE, and APC, or by using an appropriate combination of an anti-CD271 antibody and an anti-CD90 antibody. In addition, CD271+CD90+ cells can be selected by methods using magnetic beads or affinity chromatography, in addition to flow cytometry.

[0051] In addition, before using these methods, dead cells may be removed by reacting a cell population with a fluorescent dye (e.g., PI) that stains dead cells in advance and removing the fluorescently stained cells.

[0052] 3. REC Cell Concentration

[0053] Next, selected LNGFR-positive cells, or LNGFR and Thy1-positive cells, are cultured as single cells (clones), and by selecting a lot with rapid proliferation, high-purity human mesenchymal stem cells (REC: Rapidly Expanding Clone) with excellent proliferation, differentiation, and migration capabilities are obtained.

[0054] Figure 1 illustrates an REC separation process by monoclonal culture.

[0055] Mononuclear cells are prepared from human bone marrow or adipose-placental chorionic villi, and the bone marrow mononuclear cell spores are stained with anti-LNGFR alone, or anti-LNGFR and anti-Thy1. Next, using flow cytometry (cell sorter), LNGFR-positive cells, or LNGFR-positive and Thy1-positive cells, are clone-sorted into a 96-hole culture plate. That is, one cell is seeded per well. After two weeks of single-cell culture, the culture plate is photographed under a microscope, and wells that have become confluent or semi-confluent are selected, and the cells contained in those wells are designated as REC.

[0056] Here, “rapid proliferation” and “rapid proliferation” mean that when cells are sown one cell per well of a 96-hole culture plate and cultured, the culture plate becomes confluent or semi-confluent after 2 weeks or earlier from the start of culture, having a proliferation rate (doubling time of 26 ± 1 hour).

[0057] Confluent refers to a state where cultured cells cover 90% or more of the surface of the culture vessel (culture surface). Semi-confluent refers to a state where cultured cells cover 70% to 90% of the surface of the culture vessel (culture surface). The size and type of culture apparatus used can be appropriately adjusted according to the cell proliferation rate. Moderately / Slowly Expanding Cells—that is, cells that have not become semi-confluent or confluent even after two weeks of single-cell culture—are discarded. The RECs recovered from each well selected as RECs are transferred to culture flasks for each well, and cultured until they become confluent (expanded culture). Afterward, the expanded cultured cells are harvested separately. The RECs derived from one well are designated as one lot and used for the selection process described below.

[0058] Here, since the cells of the present invention are obtained by clonal sorting in which one cell is sown per well, the genetic traits of the proliferated cells are all identical. Therefore, in the present invention, the entire cell population may be referred to as a "clone," or individual cells constituting the cell population may be referred to as "clones."

[0059] In addition, in the present invention, the REC to be used for selection may be evaluated in advance by an REC marker (anti-Ror2). For example, after the above-mentioned expansion culture, adherently proliferated cells are recovered from the entire lot, and a portion of each lot (1 to 3 × 10⁶ 5 Cells (approximately 100) are divided and single-stained with a monoclonal antibody against Ror2. A method for single-staining with a monoclonal antibody against Ror2 is known (WO 2016 / 17795). In summary, the proportion of REC marker-positive cells in the recovered cells is determined by flow cytometry analysis using the REC marker. The proportion may be determined by quantifying Ror2 mRNA expression using quantitative PCR, or by manually determining the proportion using a microscope. Lots (cell populations) with a positive proportion of at least a certain value (e.g., 65%) may be accepted and used for the screening described below.

[0060] 4. Selection of the stem cell population of the present invention

[0061] In the present invention, for each lot of REC clone, it is possible to select REC of high purity and higher cell performance by investigating the cell proliferation ability, adipogenesis ability, REC-specific marker expression amount, and cell size uniformity, and analyzing the correlations thereof.

[0062] In the present invention, the coefficient of variation (CV value) of forward scattered light and the average size of the cells are used as indicators for selection.

[0063] Forward scatter is light that scatters at a small forward angle relative to the axis of the laser light. Forward scatter consists of scattered, diffracted, and refracted light of the laser light generated at the cell surface, and information regarding the size of the sample is obtained.

[0064] The coefficient of variation (CV) is the standard deviation divided by the mean value, and is a numerical value used to relatively evaluate the deviation of data with different units or the relationship between the data and the deviation relative to the mean value.

[0065] In the present invention, the CV value is selected to be 35% or less. A cell population with a CV value of 35% or less is a cell population composed of cells of uniform size. Preferably, the CV value is 30% or less, 25% or less, or 20% or less.

[0066] In addition, the average size of the cells in the cell population selected according to the present invention is 20 μm or less. Preferably, it is 18 μm or less, and is in the range of 14 μm to 18 μm.

[0067] The present invention also provides a method for evaluating the quality of a cell population of LNGFR-positive cells, or of fast-proliferating mesenchymal stem cell clones that are conjugate-positive for LNGFR (CD271) and Thy-1 (CD90). In the present invention, a cell population satisfying at least one of the following features (a) and (b), preferably both features, is determined to be of high quality.

[0068] (a) The coefficient of variation of forward scattered light in flow cytometry is 35% or less.

[0069] (b) The average cell size is 20 µm or less.

[0070] The cell population evaluated and selected in this manner is not limited to a number of cell clones constituting the population, for example, 0.8 × 10⁶ in 1 ml of solution 7 ~ 1.2 × 10⁻⁶ 7 It has about a number of cells.

[0071] In addition, the cell population in question can be applied to clinical practice for the purpose of treating, for example, the following diseases, as a therapeutic mesenchymal stem cell population. However, the diseases are not limited to these.

[0072] Genetic diseases (epidermal bullosis, hypophosphatasia, etc.)

[0073] Bone and joint diseases (knee cartilage defects, osteoarthritis degenerativeis, herniated discs, etc.)

[0074] Heart disease (myocardial infarction, ischemic heart failure, etc.)

[0075] Liver diseases (cirrhosis, non-alcoholic steatohepatitis, etc.)

[0076] Examples

[0077] The present invention will be explained in more detail below by way of examples. However, the scope of the present invention is not limited by these examples.

[0078] [Example 1]

[0079] 1. Measurement of CV values ​​of Forward Scattered Light (FSC) by flow cytometry

[0080] REC clones (clone numbers: 1 to 45) prepared in advance according to the announced method (WO 2016 / 17795) and the scheme shown in Fig. 1 were used to measure the CV values ​​of forward scattered light by flow cytometry.

[0081] In flow cytometry, FSC is proportional to the surface area or size of the cell. In this embodiment, the deviation in cell size was evaluated using the CV value of FSC as an indicator. Figure 2 shows the measurement results of the CV value of forward scattered light by flow cytometry.

[0082] (a) PI staining was performed on individual REC clones, and a gate was set on the PI-negative live cell population to exclude dead cells from analysis.

[0083] (b) The PI-negative live cell population was expanded into an FSC / SSC cytogram, and a gate (P1) was set on the main cell population to exclude dust or noise from the analysis.

[0084] (c) The cell population within the P1 gate was plotted as a histogram of FSC, and a marker (M1) was set to measure the CV value.

[0085] 2. Evaluation of cell proliferation ability and adipogenesis ability (Fig. 3)

[0086] (1) Method for evaluating cell proliferation ability

[0087] 1 × 10 5 REC cells were seeded in a 100 mm culture dish and cultured for 5 days at 37°C under a 5% CO2 environment, after which the number of cells and average cell size were measured using a cell counter. In addition, DMEM medium (Fujifilm Wako Junyako) supplemented with FBS, basic FGF, Hepes, and penicillin-streptomycin was used as the culture medium.

[0088] (2) Method for evaluating fat differentiation ability

[0089] 5 × 10 4REC cells were seeded into a 24-hole plate and cultured for 2 days at 37°C and 5% CO2. Afterward, the medium was replaced with adipogenesis induction medium and cultured for an additional 14 days. After 14 days of culture, Oil Red staining was performed, and the area of ​​the fat droplets was calculated by image analysis. In addition, the adipogenesis induction medium used was a medium prepared by adding dexamethasone, indomethacin, and IBMX to the culture medium of (1).

[0090] 3. Comprehensive Interpretation

[0091] A comprehensive analysis was performed on the REC, 45 clones obtained from one sorting (Fig. 4).

[0092] For each REC clone, the CV value of FSC, cell proliferation rate (proliferative capacity), average cell size, and adipogenesis ability were investigated. As a result, it was found that REC clones with low FSC CV values ​​(#3, #5, #15, #16, #17) had high proliferative capacity and differentiation ability, and small average cell size.

[0093] On the other hand, it was found that REC clones with high CV values ​​of FSC (#7, #32, #39, #40, #44) had low proliferation and differentiation capabilities, and large average cell size.

[0094] The average proliferation rate of clones with a CV value of 30% to 35% was 6.4, the average proliferation rate of clones with a CV value of 25% to 30% was 9.2, and the average proliferation rate of clones with a CV value of 25% or less was 15.1. In addition, the average proliferation rate of clones with an average cell size of 18 µm to 20 µm was 7.0, the average proliferation rate of clones with an average cell size of 16 µm to 18 µm was 12.7, and the average proliferation rate of clones with an average cell size of 16 µm or less was 21.3.

[0095] From these results, it became possible to select high-quality REC clones with high proliferation and differentiation capabilities, using the CV value and average cell size of FSC as indicators.

[0096] 4. Summary of typical interpretation examples (Fig. 5)

[0097] Clone A, which has a low CV value of FSC and a small average cell size, is a high-quality REC clone with high adipogenesis and proliferation capabilities.

[0098] Clone B, which has a high CV value and a large average cell size, is a non-standard REC clone with low adipogenesis and proliferation capabilities.

[0099] [Example 2]

[0100] Two types of bone marrow fluid lots (#18TL158166 and #8F5040) were sorted by two methods (CD271 and CD90 co-positive and CD271 alone) and the ratios of Colony, REC, MEC, and SEC obtained were compared (Fig. 6).

[0101] In Fig. 6, the left panel shows the results of cell sorting. Cells from the framed portion were seeded into a 96-well plate, and the proportion of colonies obtained is shown in "Colony" of the table on the right. Among the obtained colonies, the proportions of fast-growing colonies (REC), medium-growing colonies (MEC), and slow-growing colonies (SEC) are shown in the table.

[0102] Compared to the case where LNGFR and CD90 co-positives were sorted on the surface, when LNGFR was sorted alone, the colony yield was high, but the REC yield was low.

[0103] However, it was found that REC could be separated even when sorting only LNGFR positive.

Claims

Claim 1 A cell population of fast-proliferating mesenchymal stem cell clones in which LNGFR (CD271) is positive, or LNGFR (CD271) and Thy-1 (CD90) are conjugated positive, wherein the cell population satisfies the following characteristics of (a): (a) the coefficient of variation of forward scattered light of flow cytometry is 35% or less. Claim 2 A cell population having a coefficient of variation of 30% or less in claim 1. Claim 3 A cell population according to claim 1 or 2, wherein the average cell size is 20 μm or less. Claim 4 In claim 3, a cell population having an average cell size of 14 μm to 18 μm. Claim 5 A method for evaluating the quality of a cell population of fast-proliferating mesenchymal stem cell clones in which LNGFR (CD271) is positive, or LNGFR (CD271) and Thy-1 (CD90) are conjugated positive, wherein a cell population satisfying the following characteristic (a) is judged to be of high quality: (a) the coefficient of variation of forward scattered light of flow cytometry is 35% or less. Claim 6 An evaluation method in which the coefficient of variation is 30% or less, according to claim 5. Claim 7 An evaluation method according to claim 5 or 6, wherein the average cell size is 20 μm or less. Claim 8 In claim 7, an evaluation method having an average cell size of 14 μm to 18 μm. Claim 9 A method for selecting a clinically applicable cell population from a cell population of fast-proliferating mesenchymal stem cell clones in which LNGFR (CD271) is positive, or LNGFR (CD271) and Thy-1 (CD90) are conjugated positive, wherein a cell population satisfying the following characteristic (a) is selected as a therapeutic mesenchymal stem cell population: (a) the coefficient of variation of forward scattered light of flow cytometry is 35% or less. Claim 10 In Clause 9, a selection method having a coefficient of variation of 30% or less. Claim 11 A selection method according to claim 9 or 10, wherein the average cell size is 20 μm or less. Claim 12 In claim 11, a selection method having an average cell size of 14 μm to 18 μm. Claim 13 A method for preparing a cell population of human mesenchymal stem cells applicable to clinical use, comprising: (a) obtaining a population of mesenchymal stem cells that are positive for LNGFR (CD271) or positive for both LNGFR (CD271) and Thy-1 (CD90); (b) single-cell culture of a clone of the mesenchymal stem cells; (c) recovering and expanding the rapidly proliferating mesenchymal stem cell clone; (d) measuring the coefficient of variation of forward scattered light by flow cytometry for the cell population after expansion culture; and (e) selecting a cell population in which the coefficient of variation of forward scattered light by flow cytometry is 35% or less. Claim 14 A method of manufacturing according to claim 13, wherein (1) the average cell size is 20 μm or less, (2) the coefficient of variation of forward scattered light of flow cytometry is 30% or less, or (3) the average cell size is 20 μm or less and the coefficient of variation of forward scattered light of flow cytometry is 30% or less. Claim 15 A method of manufacturing according to claim 14, wherein the average cell size is 14 μm to 18 μm. Claim 16 A method of manufacturing according to claim 13, wherein in the above (c), when there are multiple fast-proliferating mesenchymal stem cell clones, the clones are recovered and cultured independently of each other. Claim 17 A method of preparation according to claim 16, wherein, in (d) above, the cell populations after the expanded culture are provided to the flow cytometry independently of each other. Claim 18 A culture of a cell population of human mesenchymal stem cells, wherein the cell population is obtained by the steps of: (a) obtaining a population of mesenchymal stem cells that are positive for LNGFR (CD271) or positive for both LNGFR (CD271) and Thy-1 (CD90); (b) single-cell culturing a clone of the mesenchymal stem cells; and (c) recovering a clone of the rapidly proliferating mesenchymal stem cells, wherein the coefficient of variation of forward scattered light of the flow cytometry of the culture is 35% or less. Claim 19 In claim 18, (1) the average cell size is 20 μm or less, (2) the coefficient of variation of forward scattered light of flow cytometry is 30% or less, or (3) the average cell size is 20 μm or less and the coefficient of variation of forward scattered light of flow cytometry is 30% or less. Claim 20 A culture according to claim 18 or 19, wherein the average cell size is 14 μm to 18 μm.